Close Menu

Lung Cancer

News and reporting on lung cancer.

New Releases: Feb 23, 2011

Premium

Sigma Life Science's new cancer cell lines

Signal has alleged that Med BioGene breached the provisions in a term sheet inked between the two companies regarding an exclusive, worldwide license for Med BioGene's LungExpress Dx test.

The device, which the scientists are developing under a two-year, €1.3 million grant from Germany's Federal Ministry of Education and Research, uses cytometric bead arrays to quantitate protein biomarkers in patients' exhaled breath condensate.

The diagnostic is being developed using a new peptoid-based technique for detecting disease-specific antibodies that could prove broadly useful as a protein biomarker discovery tool, said a researcher.

BU will use grants from NCI and DOD with partners at UCLA, Vanderbilt, and MD Anderson to develop early-stage lung cancer diagnostics.

The test is intended both for early screening purposes and the differential diagnoses of lung nodules detected during CT scans and x-rays. SomaLogic has partnered with Quest Diagnostics to commercialize the test, with a lab-developed version slated for launch next year.

The funding will go toward ongoing commercialization efforts for VeriStrat, the company's protein biomarker-based companion diagnostic for non-small cell lung cancer.

The funding will be used by Insight to develop companion diagnostics for lung cancer.

A number of prominent proteomics-based diagnostics developers were recipients of the grant and tax credit awards, which are being provided by the IRS through the Patient Protection and Affordable Care Act's Qualifying Therapeutic Discovery Project Program.

The trial plans to study whether it is cost-effective to use a genetic test and CT scans to identify smokers at risk of getting lung cancer.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.